iPSC technology has also attracted considerable interest in its potential applicability for regenerative medicine. The first clinical study using human iPSC-derived cells was initiated in 2014, which used human iPSC-derived retinal pigment epithelial (RPE) cells to treat macular degeneration4, and was reported to have improved the patient’s vision5. Although the clinical study was subsequently put on hold due to the identification of two genetic variants in iPSCs of the patient, the trial is expected to resume6.
